{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:32:32Z","timestamp":1791048752129,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.phrs.2006.12.009","type":"journal-article","created":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T12:03:32Z","timestamp":1168862612000},"page":"310-317","source":"Crossref","is-referenced-by-count":66,"title":["Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin"],"prefix":"10.1016","volume":"55","author":[{"given":"Piergiorgio","family":"Zuccaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Mombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Palmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2006.12.009_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2006.12.009_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2006.12.009_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.phrs.2006.12.009_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.phrs.2006.12.009_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCULATIONAHA.105.557652","article-title":"The issue of statin safety. Where do we stand?","volume":"111","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2006.12.009_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","article-title":"A comprehensive description of muscle symptoms associated with lipid-lowering drugs","volume":"17","author":"Franc","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00044011-200525060-00007","article-title":"Successful treatment with colesevelam HCl and pravastatin in a patient previously hospitalised with severe normal CPK myopathy on introduction of simvastatin","volume":"25","author":"Moore","year":"2005","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.phrs.2006.12.009_bib8","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcome in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2006.12.009_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2006.12.009_bib10","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"36","author":"Gambelli","year":"2004","journal-title":"J Submicrosc Cytol Pathol"},{"key":"10.1016\/j.phrs.2006.12.009_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trials","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2004.06.014","article-title":"Statin myotoxicity is associated with changes in the cardiopulmonary function","volume":"177","author":"Phillips","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2006.12.009_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2165\/00003088-199631050-00003","article-title":"Clinical pharmacokinetics of 3-hydroxy-3-metylglutaryl-coenzyme A reductase inhibitors","volume":"31","author":"Desager","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2006.12.009_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMGCoA reductase inhibitors","volume":"32","author":"Lennern\u00e4s","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2006.12.009_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd1801","article-title":"Pharmacogenetics-based therapeutic recommendations\u2014ready for clinical practice?","volume":"4","author":"Kirchheiner","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2006.12.009_bib17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mcp.2001.120251","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"Van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.phrs.2006.12.009_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","article-title":"Genetic analysis of CYP2C9 polymorphism in a Japanese population","volume":"7","author":"Nasu","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2006.12.009_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","article-title":"The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism","volume":"6","author":"Sullivan-Klose","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2006.12.009_bib21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","article-title":"Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population","volume":"254","author":"Yasar","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2006.12.009_bib22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/46.8.1072","article-title":"Rapid detection of the CYP2D6*3, CYP2D6*4, CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR","volume":"46","author":"Hersberger","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.phrs.2006.12.009_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/44.5.914","article-title":"Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication","volume":"44","author":"Steijns","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.phrs.2006.12.009_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/mcpr.1994.1007","article-title":"Rapid identification of the common Apo-E genotype using polymerase chein reaction-single strand conformation polymorphism (PCR-SSCP)","volume":"8","author":"Aozaki","year":"1994","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.phrs.2006.12.009_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/01.fpc.0000114762.78957.a5","article-title":"Lipid lowering response to statins is affected by CYP3A5 polymorphism","volume":"14","author":"Kivist\u00f6","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2006.12.009_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2006.12.009_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00041433-200204000-00001","article-title":"The apoE locus and the pharmacogenetics of lipid response","volume":"13","author":"Ordovas","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2006.12.009_bib30","first-page":"640","article-title":"Statin-induced myositis: a commonly encountered or rare side effect?","volume":"16","author":"Mukhtar","year":"2005","journal-title":"Curr Opinion Lipidol"},{"key":"10.1016\/j.phrs.2006.12.009_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2006.12.009_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.amjmed.2005.02.008","article-title":"Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization","volume":"118","author":"Charles","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.phrs.2006.12.009_bib33","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2006.12.009_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2006.12.009_bib35","first-page":"23","article-title":"Drug-induced myopathies. An overview of the possible mechanisms","volume":"57","author":"Owczarek","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.phrs.2006.12.009_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0014-2999(98)00817-6","article-title":"Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle","volume":"364","author":"Pierno","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib38","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/mol.104.000786","article-title":"Down-regulation of Na+\/Ca2+ exchanger by fluvastatin in rat cardiomyoblast H9c2 cells: involvment of RhoB in Na+\/Ca2+ exchanger mRNA stability","volume":"68","author":"Maeda","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib39","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","article-title":"Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins","volume":"25","author":"Urso","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2006.12.009_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged while lactone and acid metabolites are several-fold increased in patients in with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)66238-1","article-title":"Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?","volume":"350","author":"Nordin","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2006.12.009_bib42","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2006.12.009_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2004.09.004","article-title":"Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management","volume":"177","author":"Kajinami","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2006.12.009_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","article-title":"Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner","volume":"158","author":"Pedro-Botet","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2006.12.009_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.atherosclerosis.2004.12.019","article-title":"A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin","volume":"180","author":"Kajinami","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2006.12.009_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0021-9150(96)06031-5","article-title":"A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo-E genotype, lipoprotein(a) and insulin","volume":"129","author":"Nestel","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2006.12.009_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1024207925670","article-title":"HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins","volume":"17","author":"Gaw","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.phrs.2006.12.009_bib48","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","article-title":"Pharmacogenomics of human OATP transporters","volume":"372","author":"Konig","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2006.02643.x","article-title":"Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes","volume":"61","author":"Hedman","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2006.12.009_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01213011-200505000-00005","article-title":"Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATPB1) haplotype*17","volume":"15","author":"Niemi","year":"2005","journal-title":"Pharmacogenetics Genomics"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661807000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661807000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T18:59:12Z","timestamp":1587322752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661807000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1043661807000138"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2006.12.009","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}